Rat osteosarcoma cell line OSR-6
AssigneeThe Procter & Gamble Company
InventorsClaus-Jens W. Doersen, Robert J. Isfort
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe Procter & Gamble Company
InventorsClaus-Jens W. Doersen, Robert J. Isfort
Estimating the term…
The present invention relates to a novel cell line isolated from a rat osteosarcoma wherein the cell line has the following characteristics: a) normal p53 gene as compared to a non-tumorigenic Sprague-Dawley rat cell control; b) normal RB-1 gene as compared to a non-tumorigenic Sprague-Dawley rat cell control; c) a normal c-myc gene as compared to a non-tumorigenic Sprague-Dawley rat cell control; d) a normal c-fos gene as compared to a non-tumorigenic Sprague-Dawley rat cell control; e) a deregulated immediate early gene response; f) a canalicular network MATRIGEL.TM. growth pattern; g) tumorigenic in congenitally athymic mice; h) low levels of alkaline phosphatase activity; i) an ability to produce one or more of the following growth factors: 1) a nonheparin binding growth factor, 2) a first heparin binding growth factor, 3) a second heparin binding growth factor, 4) a third heparin binding growth factor, 5) a fourth heparin binding growth factor, 6) a fifth heparin binding growth factor, 7) a sixth heparin binding growth factor; and j) an ability to be serially propagated greater than sixty population doublings. The present invention also relates to growth factors having the characteristics of growth factors isolated from the rat osteosarcoma cell line. The present invention further relates to a process for producing such growth factors comprising growing the cells of the present invention in a culture medium and recovering the growth factors.
A cell line having all of the identifying characteristics of American Type Culture Collection Accession No. CRL 11069.
Dependencies are inferred from the claim text.